Roche reported Phase 2 data for CT‑388, a dual GLP‑1/GIP agonist, showing placebo‑adjusted weight loss of roughly 22.5 percentage points at 48 weeks in an obesity trial. The Swiss pharma said the profile is competitive with other incretin therapies and plans to advance CT‑388 into Phase 3 by the end of March. The mid‑stage readout tested multiple doses in nearly 470 participants and generated efficacy signals comparable to leading market entrants. Roche framed CT‑388 as a potential late entrant into a crowded, high‑value obesity market and emphasized plans for confirmatory pivotal studies. Investors and payers will watch safety, discontinuation rates and head‑to‑head combination strategies as Roche positions CT‑388 against incumbents from Novo Nordisk and Lilly. The result underscores ongoing pharmaceutical investment into incretin biology and next‑generation metabolic combos.